RT Journal Article
SR Electronic
T1 Omani experience with the use of factor IX Fc fusion protein
JF BMJ Case Reports
JO BMJ Case Reports
FD BMJ Publishing Group Ltd
SP e241154
DO 10.1136/bcr-2020-241154
VO 14
IS 7
A1 Shireen I Alzadjali
A1 Yasser Wali
YR 2021
UL http://casereports.bmj.com/content/14/7/e241154.abstract
AB We describe our local experience in the management of haemophilia B patients with factor IX Fc fusion protein. Two children with haemophilia B were managed with the use of a personalised/tailored dosing schedule of factor IX Fc fusion protein. Compared with the standard half-life factor IX, prophylaxis with factor IX Fc fusion protein was cost-effective, with much less injections, better bleeding control, improved tolerability or no inhibitor development.